Syverson Strege & Co’s DexCom DXCM Stock Holding History

Syverson Strege & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13	Closed	-$1.55K	–	223
2023 Q1	$1.55K	Hold	13	–	–	﹤0.01%	538
2022 Q4	$1.51K	Buy	+13	New	+$1.43K	﹤0.01%	266

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Syverson Strege & Co's DXCM Position: Q2 2023 in Review

Syverson Strege & Co sold out of DexCom (DXCM) in Q2 2023, closing a stake of 13 shares — an estimated $1.55K sold.

Syverson Strege & Co first reported a position in DXCM in Q4 2022 and held it in 2 quarters. The position peaked at $1.55K in Q1 2023. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

Syverson Strege & Co reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
Syverson Strege & Co sold 13 DexCom shares in Q2 2023, an estimated $1.55K.
Syverson Strege & Co first reported a position in DexCom in Q4 2022 and held it in 2 quarters.
Syverson Strege & Co's DexCom position peaked at $1.55K in Q1 2023.
954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.